Nearly 450 Medicines in Development For Neurological Disorders - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Nearly 450 Medicines in Development For Neurological Disorders



America’s biopharmaceutical research companies are developing 444 new medicines to prevent and treat neurological disorders, according to a new report released by the Pharmaceutical Research and Manufacturers of America (PhRMA).

More than 600 neurological disorders, ranging from well-known disorders such as epilepsy, multiple sclerosis and Parkinson’s disease, to more obscure conditions such as Duchenne muscular dystrophy and Friedreich's ataxia,  strike millions of Americans each year.

These potential medicines, all in human clinical trials or under review by FDA include:

82 medicines for Alzheimer’s disease, which afflicts more than 5 million Americans
82 for pain;  100 million US adults experience chronic pain
62 for brain tumors; nearly 70,000 Americans are diagnosed each year with a primary brain tumor
38 for multiple sclerosis, which afflicts an estimated 500,000 Americans
25 for headache, including migraine, a condition that affects more than 37 million Americans
28 for epilepsy and seizures, which impacts more than 3 million Americans
27 for Parkinson’s disease, which affects as many as 1 million Americans

Of the 444 medicines in development, many represent novel, exciting scientific approaches to target diseases, such as a gene therapy to restore neuronal function in Alzheimer’s patients, targeted therapies for neuromuscular disorders and gene therapy to restore cells damaged in Parkinson’s patients.

Source: PhRMA

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing

Click here